Study S000376

Assessment of Dose-Dependent Effects of LY2189265 on Glycemic Control in Patients With Type 2 Diabetes Treated Only With Lifestyle Interventions

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT00791479
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 167
Start: 2008-12
Primary completion: 2010-01
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:LY2189265 and Lifestyle Measures; DRUG:Placebo solution and Lifestyle Measures
Results posted: TRUE
Secondary identifiers: OTHER:H9X-MC-GBCK; REGISTRY:CTRI/2009/091/000105

Registered primary outcomes

Change From Baseline in Glycosylated Hemoglobin (HbA1c) [Baseline, 12 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021567	Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Grunberger G, Diabetic medicine : a journal of the British Diabetic Association	2012	Randomized trial	PMID 22804250 DOI	registry reference BACKGROUND:22804250